Provider Comparison · Last verified: May 8, 2026
Best GLP-1 Provider for People on SSRI: 2026 Picks for Safe, Structured Care
By Weight Loss Provider Guide Editorial Team · · Re-verified every 90 days
This page is provider comparison and education, not medical advice. If you are in crisis, 988 is the right resource — not a weight-loss intake.
Looking for the best GLP-1 provider for people on SSRI medication? Short version: most people taking an SSRI like Lexapro, Zoloft, or Prozac can safely start a GLP-1 — and on January 13, 2026, the FDA requested that drug makers remove the suicidal-thoughts warning from Saxenda®, Wegovy®, and Zepbound® labels after a review of 91 placebo-controlled trials with 107,910 patients found no increased risk. There is no major listed drug interaction between semaglutide and the most commonly prescribed SSRIs.
The real question is not can I — it is who handles this well. That is where the providers split.
Our Quick Verdict
For most people on an SSRI, Ro is the best GLP-1 provider because it offers FDA-approved options (Wegovy® pill, Wegovy® pen, Zepbound®, Foundayo™), an insurance concierge that submits prior-authorization paperwork, unlimited provider messaging, and side-effect support — the kind of structured medical care this situation actually needs.
Sesame Care is the better pick if you want a real video visit with a clinician you choose. Eden is the pick for stable SSRI users who want flat-rate compounded self-pay without an insurance fight. Lemonaid Health is one of the few platforms that prescribes both SSRIs and GLP-1s.
Check Eligibility at Ro →Get started for $39, then as low as $74/month with the annual plan paid upfront. Medication cost is separate.
What we actually verified
- FDA Drug Safety Communication, January 13, 2026 — request to remove suicidal-behavior and ideation warnings from GLP-1 obesity medications
- STEP 1, 2, 3, and 5 trial post-hoc analysis (Kushner et al., ObesityWeek 2023; Cleveland Clinic Journal of Medicine)
- Drug-interaction status between major SSRIs and semaglutide via Drugs.com
- Each featured provider's current public pricing page, eligibility page, and program page as of May 8, 2026
- Recent FDA warning-letter database for any provider we list
Pricing, state availability, and pharmacy details change. We re-verify this page every 90 days.
Quick-Pick Table: Which Provider Fits Which SSRI User
| If this is you | Start with | Why it fits |
|---|---|---|
| Stable SSRI, want structured online care with FDA-approved options | Ro | FDA-approved Wegovy® pill, Wegovy® pen, Zepbound®, Foundayo™. Insurance concierge. Unlimited messaging. |
| Stable SSRI, want a real video visit and to pick your own clinician | Sesame Care | Live video visits, lab work at Quest, provider choice, brand-name medication starting at $149/month. |
| Stable SSRI, want flat-rate compounded self-pay | Eden | Compounded semaglutide from $129 first month / $209 ongoing on the 3-month plan. Same price at every dose on compounded plans. |
| Want your antidepressant and GLP-1 managed in the same place | Lemonaid Health | One of the few platforms that prescribes both SSRIs and GLP-1s. |
| Recent psychiatric hospitalization, active suicidal thoughts, or unstable mood | Talk to your prescribing clinician first | Online intake is not the right starting point. Call or text 988 if you are in crisis. |
Get started for $39, then as low as $74/month with the annual plan paid upfront. Medication is billed separately.
Can You Take a GLP-1 If You're on an SSRI?
The short answer: Yes, in almost every stable case. SSRIs and the most common GLP-1 medications are processed by your body in different ways, and Drugs.com lists no major direct interaction for semaglutide with sertraline, escitalopram, fluoxetine, citalopram, or paroxetine. "No interaction listed" is not the same as "guaranteed safe for everyone" — but it does mean your antidepressant and your GLP-1 are not running into each other in any classic, well-documented way.
How the pathways actually work, in plain English:
Most antidepressants are broken down by your liver enzymes — the CYP450 system. The most widely used GLP-1s (semaglutide and tirzepatide) are peptides — your body breaks them down the same way it breaks down protein from food. Different roads. They don't crowd each other.
The newer FDA-approved oral medication Foundayo™ (orforglipron) is a non-peptide small molecule rather than a peptide. Current interaction databases don't show a listed major interaction with common SSRIs, but Foundayo is a newer medication and your provider should still know your full medication list.
🤢
Nausea overlap
Both medications can cause nausea, especially during GLP-1 dose escalation. Slow titration, hydration, and smaller meals manage most of it — but expect it.
⏱
Slowed stomach emptying
GLP-1s slow how fast food (and pills) leave your stomach. The Wegovy® prescribing information notes this can affect medicines that need to pass through the stomach quickly. Disclose your exact medication name and dose.
📊
Mood monitoring
Not because GLP-1s cause depression — the FDA's review found no such risk. It's because any major body change can affect mood. Track it for the first 8 weeks.
What About the FDA's "Suicidal Thoughts" Warning?
This matters for you specifically. If you have been on the fence because of headlines from 2023 — those headlines are out of date.
The original concern came from voluntary adverse-event reports in 2023–2024.
The FDA took it seriously, opened an investigation, and looked at the actual data. Nothing pointed to GLP-1s as the cause. People with obesity already have higher rates of depression, anxiety, and weight-related stress. When the full data was assessed, the medication did not make it worse.
The mental-health picture is moving in a more positive direction.
A 2026 Lancet Psychiatry national cohort study from Sweden found that among people already diagnosed with depression or anxiety, semaglutide was associated with lower risk of worsening mental illness, not higher. Important context: this was an observational study in a diabetes-prescribing context, not proof that GLP-1s treat depression or anxiety. But the signal is reassuring.
That's not a free pass.
The FDA's own statement is clear: tell your healthcare provider if you experience new or worsening depression, suicidal thoughts, or any unusual mood changes. The 988 Suicide and Crisis Lifeline is available 24/7 by call or text. Removing the warning does not remove your right to monitor yourself carefully.
Will the GLP-1 Still Work If I'm on an SSRI?
Now the nuance: A separate 2022 retrospective cohort study (Durell et al., Journal of Pharmacy Technology) looked at electronic-health-record data and found that GLP-1 weight loss was smaller in matched cohorts of antidepressant users than in matched cohorts not taking antidepressants. The bupropion cohort lost an average of −0.84 kg versus −3.46 kg in the matched no-antidepressant group. The citalopram/escitalopram cohort lost −0.73 kg versus −1.74 kg. Different population, different study type — the STEP trial data is higher quality — but worth knowing.
| If you take | What to expect |
|---|---|
| Lexapro, Celexa, Zoloft, Prozac, or Paxil | Meaningful weight loss based on STEP trial evidence. Real-world results may be modestly smaller for some people, especially early on. Track your trend, not your daily weight. |
| Wellbutrin (bupropion) | Don't assume bupropion's weight-neutral profile means more GLP-1 weight loss. The 2022 cohort study found the bupropion group actually lost less GLP-1-related weight. Bupropion is part of FDA-approved Contrave for weight loss, so the broader picture is favorable — but the GLP-1-specific data is more nuanced than internet shorthand suggests. |
| Mirtazapine or Paxil | These have the highest weight-gain profiles among antidepressants. Many people in this situation chose a GLP-1 specifically because of weight gain from these medications. Treatment can still be an option — track your response over time instead of assuming your antidepressant blocks the medication. |
Will an Online GLP-1 Provider Accept Me If I'm on an SSRI?
Almost certainly yes — if your mental health has been stable. Stable use of a single SSRI was not listed as an exclusion in the public eligibility materials we reviewed for the major U.S. telehealth GLP-1 providers. What providers screen for is recent major depression, current psychiatric hospitalization, active suicidal thoughts, and eating-disorder history.
Approved without follow-up questions.
This often happens when your SSRI has been stable and you have no recent psychiatric crisis.
Approved with a question or two.
The clinician may ask how long you have been on your dose or whether you have had any recent mood changes.
Held for a video visit or referred to in-person care.
This happens for active depression, recent hospitalization, complex polypharmacy, or eating-disorder history. A provider that defers you to in-person care is doing the right thing.
What typically does NOT disqualify you
- Stable SSRI use of any of the common antidepressants
- Anxiety disorders that are currently managed
- Past depression that has been in remission
- Past psychiatric care that ended a long time ago
What does disqualify you (or requires in-person care)
- Active suicidal thoughts or recent self-harm
- Psychiatric hospitalization within the last 6–12 months
- Active eating disorder (anorexia, bulimia, binge-eating disorder, ARFID)
- Severe gastroparesis
- Recent antidepressant change that has not yet stabilized
The Best GLP-1 Provider for People on SSRI Medication, Ranked May 2026
Here is how the major providers stack up against what SSRI users actually need: thorough medication review, follow-up access, FDA-approved options, side-effect support, insurance help, and clean regulatory standing.
| Provider | Best for | FDA-approved options | Insurance help | Provider messaging | Starting price |
|---|---|---|---|---|---|
| Ro ★ Top pick | Most SSRI users — structured care + FDA-approved + insurance help | Wegovy® pill, Wegovy® pen, Zepbound®, Foundayo™ | Yes — insurance concierge | Unlimited | $39 first month, then as low as $74/mo with annual prepay |
| Sesame Care | SSRI users who want a real video visit and to pick their own provider | Wegovy®, Zepbound®, Saxenda®, Foundayo™ (plus Ozempic®, Mounjaro® where clinically appropriate) | Accepts insurance for medications | Yes | $59/mo annual or $99/mo month-to-month (medication separate) |
| Eden | Stable SSRI users who want flat-rate compounded self-pay | Brand-name available separately | Limited | 24/7 messaging | Compounded sema from $129 first month / $209 ongoing (3-month plan) |
| Hims / Hers | Mainstream brand fans who want FDA-approved Novo Nordisk medications | Wegovy® pill, Wegovy® pen, Ozempic® | Limited | Standard | Varies; brand-name dependent |
| Lemonaid Health | People who want their SSRI and GLP-1 prescribed by one platform | Brand-name available | Limited | Standard | $129/mo intro for compounded GLP-1 + $49/mo membership |
Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality.
★ Best Overall for SSRI Users
Ro: Best Overall for Most People on SSRI Medication
Ro is our primary pick because the program is built around the kind of structured medical care that fits an SSRI user better than a low-touch self-pay path. It offers a wide set of FDA-approved GLP-1 options, an insurance concierge that handles prior authorization paperwork, unlimited messaging with your provider, side-effect and titration support, weight tracking, dose logging, and 1:1 health coaching. Pricing starts at $39 for the first month, then as low as $74/month with the annual plan paid upfront, or $149/month on the standard plan. Medication cost is separate.
Why this matters when you're on an SSRI: the headache scenario is not "Will I get approved?" — it is "Three weeks in, I'm nauseous, my mood feels off, and I can't reach anyone." Ro's unlimited provider messaging is the answer to that scenario. You message, a clinician answers. That is the difference between a medical service and a subscription that ships you a vial.
Ro's FDA-approved GLP-1 formulary (current as of May 8, 2026):
- Wegovy® pill (oral semaglutide) — first FDA-approved semaglutide pill for weight loss; ~14% average body weight loss at 64 weeks in clinical trials
- Wegovy® pen (injectable semaglutide)
- Zepbound® pen and KwikPen (tirzepatide)
- Foundayo™ (orforglipron) — newer FDA-approved oral GLP-1, FDA-approved April 1, 2026
Who Ro is best for:
- You take an SSRI and want a structured, monitored online process
- You want FDA-approved medication rather than starting with compounded
- You may have insurance coverage and want help getting it activated
- You want to message a clinician about side effects
- You'd rather pay more for the right setup than save $50/month on a less supported program
Who Ro is NOT best for:
- You want the absolute lowest possible monthly cash price
- You don't want a membership model
- You strongly prefer a live video visit (Sesame fits that better)
- You're on Medicaid — Ro's Body Program is not currently available
Get started for $39, then as low as $74/month with the annual plan paid upfront. Medication is billed separately.
Best for Video Visits
Sesame Care: Best If You Want a Video Visit and to Pick Your Own Provider
Sesame Care is our pick for SSRI users who want live, face-to-face care and the option to choose a clinician they're comfortable with. Sesame's weight-loss program publicly lists ongoing video visits, dedicated provider care, lab work at Quest Diagnostics, unlimited messaging, and insurance acceptance for medications. The membership is $59/month with an annual subscription, or $99/month month-to-month. Medication costs are separate. Sesame is one of the few programs that publishes cash-pay GLP-1 pricing — branded medications start at $149/month without insurance.
For an SSRI user, the value of Sesame is real and specific: you get to pick the clinician. If you want someone openly comfortable with patients on psychiatric medication, you can read provider bios and choose accordingly. Most other telehealth platforms assign you whoever is in the queue. Sesame doesn't.
Who Sesame is best for:
- You want a live video visit before taking any medication
- You want to choose your own clinician
- You want labs ordered and reviewed (and aren't in a lab-exception state)
- You want the broadest FDA-approved formulary
- You're paying cash and want predictable, transparent pricing
Who Sesame is NOT best for:
- You want everything bundled into one subscription price
- You want a fully asynchronous, no-appointment experience
- You need guaranteed insurance approval
$59/month annual or $99/month month-to-month. Lab work included at Quest except in AZ, HI, ND, NJ, NY, OK, RI, SD, and WY. Medication cost separate.
Best Flat-Rate Compounded
Eden: Best for Stable SSRI Users Who Want Flat-Rate Compounded Self-Pay
Eden is the right pick for readers whose SSRI has been stable for a while and who want a no-insurance, flat-rate compounded path. Eden's public program description states that board-certified doctors review your full health history before deciding whether a GLP-1 medication is appropriate.
Current Eden pricing (May 8, 2026):
- Compounded semaglutide, 3-month plan: $129 first month, $209/month after
- Compounded semaglutide, monthly plan: $149 first month, $229/month after
- Compounded tirzepatide: $249 first month, $329/month after
- Brand-name FDA-approved options are available at much higher pricing: Ozempic® $1,399/mo, Zepbound® $1,399/mo, Wegovy® $1,695/mo, Mounjaro® $1,399/mo. The same-price-at-every-dose language Eden advertises applies to its compounded plans only.
Who Eden is best for:
- Your SSRI has been stable for at least 3 months
- You don't want to deal with insurance
- You want flat-rate pricing that doesn't increase with dose escalation
- You're comfortable with compounded medication after reading the FDA disclosure
Who Eden is NOT best for:
- You want insurance help — Ro is much better here
- You want a video visit by default — Sesame is better here
- You want guaranteed FDA-approved medication only
- You want to see a clinician's name and credentials before booking
Compounded semaglutide from $129 first month / $209 ongoing on the 3-month plan. Compounded medications are not FDA-approved.
Honest Mentions: Hims, Hers, and Lemonaid Health
Hims and Hers
Legitimate FDA-approved options after the March 2026 Novo Nordisk partnership gave them broad access to Wegovy® pill, Wegovy® pen, and Ozempic®. A fine choice if you already use Hims or Hers for something else and want to keep your care under one familiar brand. For transparency: in September 2025 the FDA issued a warning letter to Hims & Hers Health (dba Hers) regarding compounded-semaglutide marketing claims. The compounded business has shifted dramatically since then — the Novo Nordisk partnership represents the new direction. We disclose the history because honest disclosure is the standard of this page, not because it is a current dealbreaker.
Lemonaid Health
One of the few platforms that prescribes both anxiety and depression medications — including SSRIs like Lexapro, Zoloft, and Prozac — and GLP-1s. That is a real differentiator if you want to consolidate care. Compounded GLP-1 pricing starts at $129/month for a limited time, with a separate $49/month weight-loss membership. Note: we did not verify that the same clinician coordinates both service lines, and the GLP-1 menu is smaller than Ro's or Sesame's.
Why we didn't include MEDVi on this page
MEDVi is a well-known compounded GLP-1 provider. For this page — readers on an SSRI who are already safety-conscious — we chose to feature providers without recent FDA correspondence on compounded-marketing language. If you are looking specifically for compounded GLP-1 access at flat rates, our broader provider comparison covers MEDVi in detail.
Should People on SSRI Choose FDA-Approved or Compounded GLP-1?
For most safety-anxious SSRI users, FDA-approved medication is the cleaner choice. It removes one whole layer of uncertainty — about formulation, sterile-fill procedures, and what the FDA could enforce next. Compounded medications can still be a reasonable option for stable readers focused on cost, but the disclosures and questions are different.
FDA-approved medications
Wegovy®, Zepbound®, Saxenda®, and Foundayo™ have been reviewed by the FDA for safety, effectiveness, and manufacturing quality. They are the medications studied in the clinical trials that produced the weight-loss data everyone references.
- Less to monitor on top of mood changes
- Easier psychiatrist coordination — they know Wegovy® from the literature
- Insurance coverage actually exists via prior authorization
Compounded medications
Prepared by licensed pharmacies for individual patients. Not FDA-approved. Not reviewed by the FDA for safety, effectiveness, or quality. They came into wide use during recent shortages. The FDA has specifically warned that compounded products cannot be marketed as "the same as," "generic versions of," "the same active ingredient as," or "clinically proven like" the FDA-approved drugs.
- Lower cost, but additional formulation uncertainty
- Cash-pay only; no insurance
- Ask: which pharmacy, what formulation, what happens if FDA enforcement changes
Which Provider Fits Which SSRI Situation?
Pick your provider by your situation, not by the lowest advertised price.
| Your situation | Best starting point | Why |
|---|---|---|
| Stable single SSRI for 6+ months, no recent crisis | Ro or Eden | Standard intake will likely accept; pick on whether you want insurance help (Ro) or flat compounded self-pay (Eden) |
| SSRI plus Wellbutrin (or Wellbutrin alone) | Ro or Sesame | Bupropion's effect on GLP-1 weight loss is mixed; pick on the level of monitoring you want |
| Multiple psychotropics (SSRI plus benzo, plus stimulant, plus mood stabilizer) | Sesame Care | The video visit and provider-choice model handles complex medication lists better |
| SSRI dose changed in the last 3 months | Talk to your psychiatrist first, then Ro or Sesame | Stability matters before adding a new medication |
| History of major depression episode within last 2 years | Sesame Care with a chosen clinician, or in-person | Most platforms mirror trial-style exclusions for recent MDD |
| Active suicidal thoughts or recent psychiatric hospitalization | Do not start through generic telehealth | Call or text 988. This page is not the right resource — your existing care team is |
| You want FDA-approved brand-name medication with insurance help | Ro | Broadest FDA-approved formulary, insurance concierge |
| You want both your SSRI and GLP-1 prescribed in one place | Lemonaid Health | One of the few platforms with both |
Still not sure where you fit?
Five questions about your antidepressant, history, and preferences. We'll point you to a provider that matches your specific situation.
Take our free 60-second matching quizOne Thing We'll Be Straight With You About
Some online GLP-1 providers will approve you in five minutes, with no real screening, regardless of what you tell them about your psychiatric history. From a "click and ship" standpoint that sounds reader-friendly. From a safety standpoint — especially if you're on an antidepressant — it's the opposite of what you want.
We've watched this dynamic play out across the industry for two years. Providers compete to remove friction. Friction gets reframed as a customer-experience problem. Mental-health questions on the intake form start to feel like obstacles rather than safeguards. In the worst cases, the intake never asks at all.
The reason we recommend Ro as the primary pick on this page is that Ro doesn't optimize for the fastest possible approval. The intake reviews your full medication list, the program includes provider messaging so you can flag mood or side-effect concerns in real time, and the formulary is FDA-approved medication you can verify against your own pharmacy's records. That's slightly more friction. For someone on an SSRI, that friction is the value.
What to Tell Your Psychiatrist (and Your GLP-1 Prescriber) Before You Start
Tell both prescribers, in writing if possible, exactly what medications you are considering and what you are already taking. They do not share records automatically. You are the one who connects them. The conversation takes about ten minutes total, but it prevents 90% of the problems people run into.
What to say to your psychiatrist
"I'm thinking about starting a GLP-1 medication for weight loss — possibly Wegovy®, Zepbound®, or Foundayo™ through an online provider. I've read that the FDA requested removal of the suicidal-ideation warning in January 2026 and that the STEP trials showed people on antidepressants lost similar amounts of weight. I want to make sure you're comfortable before I start. Are there any concerns you'd want to flag, and would you be willing to coordinate if questions come up during the first few months?"
If your psychiatrist hesitates, ask why specifically. Common reasons:
"Wait until you're more stable on the SSRI." Reasonable if you are newly on the medication or just changed your dose. We use 3 months of stable dosing as a screening rule before recommending low-touch telehealth.
"You may have nausea — let's pick a strategy." Reasonable. Both medications can cause early nausea. Slow titration solves most of it.
"I want to track your mood through this." Excellent. Say yes. Schedule a check-in at the 4-week and 12-week mark.
What to say to your GLP-1 prescriber
In the "current medications" or "additional information" box of your intake, copy and paste this:
"I take [medication name] [dose] [frequency] for [condition], prescribed by [Dr. Name], and I've been stable on this dose since [month/year]. My most recent psychiatric appointment was [month]. No psychiatric hospitalizations or self-harm in the past two years. I [also/do not] take [other psychiatric medications]. I [do/do not] have a history of an eating disorder. Please let me know if you need any additional history before deciding whether a GLP-1 is appropriate."
What to do if your prescribers disagree
This happens. Your GLP-1 telehealth provider says you're approved; your psychiatrist isn't sure. Don't push through and hope it works out.
- Pause and have the conversation. Ask your psychiatrist what specifically would change their answer. Often it's a few months of stability, a check-in appointment, or a specific medication choice they'd be more comfortable with.
- Switch to a video-visit provider like Sesame Care. Pick a clinician with experience in psychiatric comorbidity and have them coordinate directly with your psychiatrist via a release of records.
The SSRI + GLP-1 Intake Prep Checklist
Before your first GLP-1 visit, write down or screenshot the following. This checklist is built specifically for SSRI users — not the generic "tell us about your health" form most providers walk you through. Bring this list to your intake. It saves you twenty minutes of back-and-forth.
Medications and history
- Current SSRI: name, dose, how many times per day, time of day you take it
- How long you've been on this exact dose (months/years)
- Any other psychiatric medications: name, dose, frequency
- PRN ("as needed") medications: benzodiazepines, sleep aids, ADHD medications
- Any recent psychiatric medication change in the last 3 months
- Last appointment with your psychiatrist or PCP
- Date of any prior psychiatric hospitalization, if applicable
- Any current diagnoses (depression, anxiety, OCD, PTSD, ADHD, bipolar, etc.)
Mental health baseline
- Current mood on a 1–10 scale this week (write it down — useful baseline)
- Current anxiety on a 1–10 scale this week
- Sleep quality this past week
- Any thoughts of self-harm in the last 6 months — be honest with yourself, and bring this to your prescribing clinician before starting any GLP-1 intake
- Any history of an eating disorder
GI and physical health
- Any history of pancreatitis or thyroid cancer (GLP-1 contraindications)
- Any reflux, gastroparesis, or chronic stomach issues
- Current weight and height
- Any other chronic medications (diabetes, blood pressure, thyroid, hormones)
- Allergies to medications
Practical info (bring to intake)
- Insurance information (for Ro's concierge or Sesame's coverage check)
- HSA/FSA card if applicable
- Preferred pharmacy (some providers route to local pharmacies)
- Your monthly budget for medication and program fees combined
5 Mistakes to Avoid When Starting a GLP-1 on an SSRI
The most common mistakes have nothing to do with the medication itself — they're about how people approach the decision.
Hiding your antidepressant on the intake form
We get it — you're worried you'll be rejected. But skipping the question is the worst version of efficient. Telehealth providers cannot help you safely if they don't know what else is in your system. Disclose. It almost never gets you rejected, and when it does, that rejection was the right answer.
Choosing the cheapest provider first
For most weight-loss decisions, price is a fine first filter. For SSRI users specifically, monitoring quality matters more than $50/month. The provider that approves you in eight minutes and ships you a vial isn't doing you a favor. Pay a little more for the program that has provider messaging, follow-up, and side-effect support. You'll thank yourself by week six.
Changing your antidepressant and starting your GLP-1 at the same time
If you have a side effect — nausea, mood dip, sleep change, anxiety — you'll have no idea which medication caused it. Pick one change at a time. Get stable. Then make the next move. This is the single most-given piece of advice from psychiatrists who manage GLP-1 patients, and the most ignored.
Believing "no interaction listed" means "no monitoring needed"
Drug-interaction databases list no major interaction between common SSRIs and semaglutide. That is the documented fact. It does not mean "set it and forget it." Both medications can affect appetite, mood, sleep, and energy. You are the only one who knows what feels normal for you. Track it.
Buying compounded GLP-1 without understanding what compounded means
Compounded medications are made by a licensed pharmacy for a specific patient based on a prescription, but they are not FDA-approved. They have not been reviewed for safety, effectiveness, or quality the same way Wegovy® or Zepbound® have. The FDA has explicitly warned that some marketers make misleading claims about compounded GLP-1s. If you're worried about safety as an SSRI user, FDA-approved is the cleaner choice.
When NOT to Use Online GLP-1 Telehealth
Active suicidal thoughts or recent self-harm.
Call or text 988 (Suicide and Crisis Lifeline). Don't fill out a weight-loss form first. Get the immediate support you need; the GLP-1 question can wait three weeks.
Psychiatric hospitalization in the past 6–12 months.
Your psychiatrist or treating clinician should be the one initiating any major new medication while you're still stabilizing.
An active eating disorder.
Anorexia, bulimia, binge-eating disorder, ARFID. Appetite-suppressing medication in the middle of disordered eating is dangerous in ways most telehealth providers aren't equipped to handle. If you're unsure, the National Alliance for Eating Disorders helpline can connect you with in-person care.
Pregnancy or trying to conceive.
GLP-1s are not recommended during pregnancy.
Severe gastroparesis or another condition where stomach emptying is already impaired.
Adding a GLP-1 makes this worse.
You changed your antidepressant within the last 30–60 days.
Wait until you're stable. Your prescriber will tell you when.
If any of these apply, the right CTA isn't a provider link — it's a conversation with someone who already knows you. We mean that. We'd rather you bookmark this page and come back in a few months than push through now.
Frequently Asked Questions
How We Built This Comparison
Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We don't sell medication. We don't operate a pharmacy. We compare what providers publicly offer, verify it against current sources, and explain which provider is the best fit for which reader.
For this specific page, we verified the FDA's January 13, 2026 Drug Safety Communication; read each featured provider's current public program, pricing, and eligibility pages as of May 8, 2026; cross-checked drug-interaction status between major SSRIs and semaglutide via Drugs.com and FDA prescribing information; reviewed the STEP trial post-hoc analysis (Kushner et al., 2023), the 2022 Durell et al. retrospective cohort study, and the 2026 Lancet Psychiatry national cohort study from Sweden; and checked the FDA warning-letter database for any provider we considered featuring.
We earn affiliate commissions when readers click through to certain providers — Ro, Sesame Care, Eden, Hims, Hers — and start a program. That financial relationship is real, and we disclose it. It does not change our recommendations. The reason Ro leads this specific page is that Ro's structured care and FDA-approved formulary fit safety-anxious SSRI users better than the alternatives. If a different provider were the better editorial fit, we'd put them first.
We re-verify this page every 90 days. The "Last verified" date at the top reflects the most recent full check. If you spot an error, write us: [email protected].
Still Not Sure Which GLP-1 Program Is Right for You?
Take our free 60-second matching quiz. Five questions about your antidepressant, your history, and what you're looking for. We'll route you to the provider that fits your specific situation — without a sales pitch.
Find My MatchThis page is provider comparison and education, not medical advice. Always consult your psychiatrist, primary care clinician, or other qualified healthcare provider before starting, stopping, or changing any medication. If you're in crisis, call or text 988 (Suicide and Crisis Lifeline).
Sources and Citations
- U.S. Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications. Drug Safety Communication, January 13, 2026.
- Kushner RF, Fink-Jensen A, Frenkel O, et al. Semaglutide 2.4 mg in people with or without antidepressants at baseline: a post-hoc analysis. Presented at ObesityWeek 2023; reported in Cleveland Clinic Journal of Medicine and Medscape, October 2023.
- Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study. The Lancet Psychiatry, April 2026.
- Durell N, Franks R, Coon S, Cowart K, Carris NW. Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss. Journal of Pharmacy Technology, 2022.
- Drugs.com semaglutide drug-interaction profile. Accessed May 8, 2026.
- Wegovy® prescribing information. Novo Nordisk. wegovy.com/prescribing-information.html.
- Ro Body Program pricing, insurance, and program pages. ro.co/weight-loss/. Verified May 8, 2026.
- Sesame Care online weight-loss program. sesamecare.com/service/online-weight-loss-program. Verified May 8, 2026.
- Eden GLP-1 treatment page. tryeden.com/treatment/glp-1-treatments. Verified May 8, 2026.
- Lemonaid Health weight-loss services. lemonaidhealth.com/services/weight-loss. Verified May 8, 2026.
- Hims Inc. Novo Nordisk's FDA-Approved GLP-1s Now Available With Hims & Hers (March 2026 announcement).
- U.S. Food and Drug Administration. Hims & Hers Health, Inc. dba Hers Warning Letter, 716825-09092025.
- 988 Suicide and Crisis Lifeline. 988lifeline.org.